CeriBell (CBLL) Projected to Post Quarterly Earnings on Tuesday

CeriBell (NASDAQ:CBLL) is expected to release its Q3 2025 results after the market closes on Tuesday, November 4th. Analysts expect CeriBell to post earnings of ($0.43) per share and revenue of $21.7760 million for the quarter. CeriBell has set its FY 2025 guidance at EPS.Interested persons can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Tuesday, November 4, 2025 at 4:30 PM ET.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.02. CeriBell had a negative net margin of 63.83% and a negative return on equity of 48.42%. The company had revenue of $21.20 million during the quarter, compared to analysts’ expectations of $20.52 million. On average, analysts expect CeriBell to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

CeriBell Trading Up 0.7%

Shares of NASDAQ CBLL opened at $11.40 on Friday. CeriBell has a 1 year low of $10.01 and a 1 year high of $32.75. The stock has a market cap of $417.92 million and a P/E ratio of -3.81. The firm has a 50-day moving average of $12.08 and a 200 day moving average of $14.67. The company has a debt-to-equity ratio of 0.11, a current ratio of 13.31 and a quick ratio of 12.91.

Insiders Place Their Bets

In other CeriBell news, CTO Raymond Woo sold 11,112 shares of the firm’s stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $12.54, for a total transaction of $139,344.48. Following the completion of the sale, the chief technology officer directly owned 167,704 shares in the company, valued at approximately $2,103,008.16. This trade represents a 6.21% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 20.10% of the company’s stock.

Institutional Trading of CeriBell

A number of institutional investors and hedge funds have recently bought and sold shares of CBLL. JPMorgan Chase & Co. increased its stake in CeriBell by 6,424.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 380,003 shares of the company’s stock valued at $7,117,000 after purchasing an additional 374,179 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of CeriBell by 109.9% during the second quarter. Rhumbline Advisers now owns 32,806 shares of the company’s stock valued at $614,000 after purchasing an additional 17,177 shares during the last quarter. New York State Common Retirement Fund raised its holdings in shares of CeriBell by 148.6% during the second quarter. New York State Common Retirement Fund now owns 8,700 shares of the company’s stock valued at $163,000 after purchasing an additional 5,200 shares during the last quarter. Quantbot Technologies LP raised its holdings in shares of CeriBell by 70.3% during the second quarter. Quantbot Technologies LP now owns 15,504 shares of the company’s stock valued at $290,000 after purchasing an additional 6,401 shares during the last quarter. Finally, Invesco Ltd. purchased a new position in shares of CeriBell during the second quarter valued at approximately $197,000.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on CBLL. Weiss Ratings reissued a “sell (e+)” rating on shares of CeriBell in a research report on Wednesday, October 8th. Raymond James Financial initiated coverage on shares of CeriBell in a research report on Tuesday, October 21st. They set a “strong-buy” rating and a $19.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $30.50.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.